SAN MATEO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced it has raised over $31 million in a Series F financing to accelerate the commercial adoption of a neurovascular intervention […]
Other News
Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry
Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper Vascular Access WAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical registry […]
Life-saving inventor Shelley Savage wins two Business Worldwide Magazine Global Corporate Excellence Awards
LONDON, Nov. 16, 2023 /PRNewswire/ — Founder and CEO of CardioThrive, Shelley Savage has dedicated her career to saving lives. Her company’s patented invention, the PocketDefib™, has the potential to dramatically reduce the number of deaths caused by SCA (Sudden cardiac arrest) all over…
Enlitic to Showcase Cutting-Edge Solutions at RSNA Annual Meeting 2023
FORT COLLINS, Colo., Nov. 15, 2023 (GLOBE NEWSWIRE) — Enlitic®, a pioneering force in the realm of medical imaging data management, is gearing up for its participation in the Radiological Society of North America (RSNA) Annual Scientific Assembly and Meeting 2023. Enlitic is entering this year’s meeting with an unwavering […]
Flow Therapy and The Christ Hospital Presenting the Results of EECP® on Angina with No Obstructive Coronary Arteries (ANOCA)
Patients undergoing non-invasive treatment show significant improvement in frequency of chest pain, exercise capacity and quality-of-life markers FORT WORTH, Texas, Nov. 15, 2023 /PRNewswire/ — Enhanced External Counterpulsation (EECP®), a non-invasive treatment that increases blood…
Route 92 Medical Announces Impressive Clinical Results for its Tenzing® Technology.
Multicenter clinical study showcases how Tenzing® technology is improving neurovascular intervention outcomes SAN MATEO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced compelling results from a multicenter clinical study1 on the […]
LIB Therapeutics Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep, a Novel Third-Generation PCSK9 Inhibitor in Development for Cardiovascular Disease
CINCINNATI–(BUSINESS WIRE)–LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD. These two trials are part of the registration-enabling Phase 3 LIBerate Pro
New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)
Data presentations at AHA 2023 Meeting reinforce treatment with XARELTO® plus aspirin consistently reduces major cardiovascular events (MACE) as well as major adverse limb events (MALE) in complex patients with PAD Janssen continues commitment to supporting PAD patients with ongoing…
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 6,996,922 […]
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patients BACKBEAT pivotal study on track to start enrollment before the end of 2023, with a mid-2025 target for completion of enrollment Expected operating cash runway sufficient into […]
Recent
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
New Minimally Invasive Therapy at MemorialCare Heart & Vascular Institute Reduces Cardiovascular Mortality by Nearly 30% in Patients with Resistant Hypertension
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Popular
- No commented posts yet